223 Users Online
Nasal Allergy Treatment Market Segmented By Treatment - Immunotherapy | Antihistamines | Decongestants | Corticosteroids | Nasal Allergy Treatment Accounted for 74.1% Share
The global nasal allergy treatment market is set to display substantial growth at a 4% CAGR from 2022 to 2032, with a market value of around US$ 14.1 billion as of 2021. As per this Persistence Market Research study, retail pharmacies accounted for a substantial market share of 45.4% in 2021.
Following exposure to inhaled allergens in atopic patients, nasal allergy, or allergic rhinitis (AR), a non-infectious inflammatory condition of the nasal mucosa, is mediated by IgE and involves several immune cells and cytokines. Numerous topics have been explored in relation to the epidemiology of AR, including prevalence, disease classification, allergen sensitivity, co-morbidities, adverse outcomes, genetic disposition, and expenses. The prevalence of AR is still rising globally, particularly in low- and middle-income nations.
Nasal allergy treatment accounted for 74.1% share of the global allergy treatment market in 2021.
|
Nasal Allergy Treatment Market Value 2021 |
US$ 14.1 Billion |
|
Estimated Market Value (2022) |
US$ 14.5 Billion |
|
Forecasted Market Value (2032) |
US$ 21.4 Billion |
|
CAGR (2022 to 2032) |
4% |
|
Market Share of Top 5 Countries |
59.5% |
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
The global market exhibited growth at a CAGR of 2.7% from 2017 to 2021.
Once AR has been diagnosed, the standard of care calls for a treatment plan that takes the severity of the condition, the presence of coexisting allergy conditions, and-most importantly-a collaborative decision-making approach that takes the patient's preferences into account. The conventional treatment plan for AR starts with allergen avoidance, which includes limiting exposure to relevant allergens, keeping indoor humidity below 40% to keep dust mites and mold at bay, and using high-efficiency particulate air (HEPA) filters to filter allergens out of the air that is breathed in.
If avoidance tactics fail to relieve the symptoms, the patient is informed of pharmacological options. Starting with antihistamines and intranasal glucocorticoids, the initial line of treatment is symptomatic.
Additionally, a key factor projected to fuel the growth of the market is rising awareness among people across the world regarding allergic responses. Moreover, drug producers are encouraging expansion by offering a range of drug administration modalities accessible. The market is anticipated to expand due to the high-quality medications and nasal sprays produced by manufacturers for the efficient treatment of nasal allergy.
Furthermore, heavy tobacco use is another element that raises the incidence of allergic rhinitis. The rising use of tobacco is driving growth in the global market for allergic rhinitis. Expansion of the global market for nasal allergy treatment has been positively anticipated as a result of these factors. The market is expected to expand at a CAGR of 4% over the next ten years.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized VersionWHO has highlighted the importance of digital technology in advancing national health systems and achieving the health-related Sustainable Development Goals, which include universal health coverage. Self-monitoring via an electronic diary, customized feedback, and patient-specific education are some advantages of mobile technology.
Their use could improve and enhance patients' ability to control their own care in daily life. This method offers patients a practical and affordable choice, especially in low- and middle-income nations where transportation problems and high costs are key issues. Mobile technology helps increase treatment adherence by tailoring the care to each patient's condition and needs.
For instance, daily medicine intake can be seen using the smartphone camera for direct or indirect verification by healthcare professionals. This monitoring system makes it possible to identify any problems with adherence to the prescribed treatment, which enables patients to get counseling and the treatment to be adjusted as necessary.
Thus, the adoption of digital health technologies by patients with a nasal allergy could introduce enhanced treatment outcomes, along with patient monitoring, as well as better compliance with treatment.
Although allergy immunotherapy is thought to be the sole etiological treatment for AR that is also the most effective, it has several drawbacks, including significant expense, systemic adverse effects, prolonged duration of treatment, and lack of biomarkers to track and predict therapeutic performance.
Additionally, despite the fact that most patients respond well to pharmacotherapy, many have trouble taking their medications as prescribed. Additionally, 2nd-gen oral antihistamines have significant H1 receptor selectivity and minimal anticholinergic action, while first-generation antihistamines are no longer advised due to their adverse effects.
In addition, placental extract submucosal injections are a relatively new therapeutic approach that is gaining popularity. For a total of 24 weeks, the extract, which possesses angiogenic and mitogenic activity, is injected into each nasal cavity once a week. But even if nasal symptom alleviation is achieved, recurrence following the end of treatment may be observed.
Thus, the high cost of treatment, long duration of therapy, and poor patient compliance, as well as adverse effects associated with the pharmacological options for nasal allergy treatment are factors having a restrictive impact on global market expansion.
Sales Team
Client Partner
What Makes the United States the Largest Market for Nasal Allergy Treatment?
The United States dominated the global market with 36.7% share in 2021. The country presents a large population with nasal allergies, most of which are introduced seasonally.
Through an established paradigm of care, patients in the country have access to several reimbursement programs for nasal allergy treatment, offered by Medicare and Medicaid Services. Moreover, greater patient education on the symptoms and management of nasal allergies has further propelled the growth of the market in the country.
Why is China Considered a Lucrative Market for Nasal Allergy Treatment?
China accounted for a market share of 8.7% in 2021. In China, nasal allergy is a serious medical, economic, and public health issue. AR is a significant risk factor for numerous diseases and disorders, particularly in youngsters.
The general public has been significantly impacted by the trend of increasing AR incidence in recent years. This alarming growth underscores the urgent need for greater comprehension of the prevalent state and attributes, sensitivity patterns, and related risk factors of AR to enhance treatments and establish effective preventive measures.
What is the Outlook of the United Kingdom Market for Nasal Allergy Treatment?
The United Kingdom holds a market share of around 3.4%.
With a large population of smokers, the incidence of allergic rhinitis is high in the country, thus propelling the demand for nasal allergy treatment.
Which Nasal Allergy Treatment is Widely Adopted Globally?
Corticosteroids accounted for a market share of 30.7% in 2021. Steroids in the form of corticosteroids are used to treat allergic asthma as well as the swelling and inflammation brought on by allergies. A variety of allergies can be treated with corticosteroids. Depending on how severe the illness is, they can be taken either temporarily or permanently.
These medications are mainly used to treat chronic conditions. They are particularly helpful in managing inflammation, which is a chronic underlying consequence of many conditions, including allergies.
Which Disease is of Large Concern in This Market?
Perennial allergic rhinitis held a market share of 45% in 2021. Chronic inhalation of indoor allergens or a severe allergic reaction to plant pollens during successive seasons are the two main causes of perennial allergic rhinitis.
Nasal symptoms, such as sneezing and nasal congestion, are the main features of perennial rhinitis. It happens as a result of an overreaction to an environmental trigger, which causes inflammation of the nose's lining. Although it resembles hay fever, the allergens that produce the allergic reaction are prevalent all year round, thus leading to a larger market share.
Which is the Most Preferred Route of Administration for Nasal Allergy Treatment?
The nasal route of administration accounted for a market share of 41.1% in 2021. Drugs that are only available through intravenous administration can also be administered via the nasal route to reach systemic circulation. This is a result of the extensive surface area, permeable endothelium membrane, high total blood flow, prevention of first-pass metabolism, and easy accessibility.
Bioadhesive drug delivery devices are most suited for the nasal mucosa, presenting opportunities for novel treatment modalities for nasal allergies, thus propelling the growth of this segment during the forecast period.
Which Distribution Channel Greatly Benefits Nasal Allergy Treatment Providers?
Retail pharmacies enjoyed a market share of 45.4% in 2021. Based on their symptoms, retail pharmacists can assist allergy sufferers in finding the appropriate steroid or decongestant nasal sprays, oral antihistamines or decongestants, and eye drops.
Nasal allergies can be entirely addressed without a doctor's visit or prescription using over-the-counter drugs. Because there are so many OTC treatments for allergy symptoms, retail pharmacists are in a unique and significant position to support allergy patients start treatment.
The market for nasal allergy treatment is a fragmented space. Key players are expanding their research and developmental activities for the launch of novel products. Market players also resort to strategic mergers and collaborations to expand their product portfolios and enhance their pipelined products.
For instance:
|
Attribute |
Details |
|
Forecast Period |
2022 to 2032 |
|
Historical Data Available for |
2017 to 2021 |
|
Market Analysis |
US$ Million for Value |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Companies Covered |
|
|
Key Market Segments Covered |
|
|
Pricing |
Available upon Request |
By Treatment:
By Disease:
By Route of Administration:
By Distribution Channel:
By Region:
The global nasal allergy treatment market reached US$ 14.1 billion in 2021 and is set to expand 1.5X over the next ten years.
The market is expected to reach US$ 21.4 billion by 2032, expanding at a CAGR of 4%.
Growing geriatric population, rising burden of chronic respiratory diseases, and increasing R&D on novel biopharmaceuticals are key trends in this market.
North America accounted for 37.3% share of the global market in 2021.
The market in Europe is projected to grow at a CAGR of 4.2% during the forecast period.
The U.S., U.K., China, Japan, and Germany are expected to drive huge demand for nasal allergy treatment.
Merck & Co., Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline PLC, Sanofi S.A., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Alcon (Novartis AG), Stallergenes Greer, Allergy Therapeutics, ALK-Abelló A/S, Hanmi Pharmaceutical, Immunotek, Regeneron Pharmaceuticals, Abdi Ibrahim Pharmaceuticals, and Glenmark, are key market players.
